 BURLINGTON, Mass., Aug. 25, 2021 GLOBE NEWSWIRE -- Flexion Therapeutics, Inc. Nasdaq:FLXN today announced the expansion of the Phase 1b randomized, double-blind, placebo-controlled trial of FX301 in patients undergoing bunionectomy. FX301 is a novel formulation of a locally administered NaV1.7 inhibitor funapide which aims to provide at least three to five days of post-operative pain relief while preserving motor function. The companys decision to advance FX301 into the expansion cohort follows a review of safety data from the single ascending dose stage of the trial by an independent Safety Monitoring Committee. Subsequently, an internal review committee assessed safety, systemic exposure and efficacy data and made the decision to advance the program. 